Use of once‐weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study

AIM: To investigate once‐weekly (OW) semaglutide, a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), in patients with type 2 diabetes (T2D) in routine clinical practice. METHODS: The SURE Canada study was a multicenter, prospective, observational study. Adults with T2D and one or more documented...

Descripción completa

Detalles Bibliográficos
Autores principales: Yale, Jean‐François, Catarig, Andrei‐Mircea, Grau, Katrine, Harris, Stewart, Klimek‐Abercrombie, Agnieszka, Rabasa‐Lhoret, Rémi, Reardon, Laura, Woo, Vincent, Liutkus, Joanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291287/
https://www.ncbi.nlm.nih.gov/pubmed/34142429
http://dx.doi.org/10.1111/dom.14468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291287/
https://www.ncbi.nlm.nih.gov/pubmed/34142429
http://dx.doi.org/10.1111/dom.14468

Ejemplares similares